Phase 1-2 UMBRELLA Trial Evaluating Isatuximab With or Without Dexamethasone in Combination With Novel Agents in Relapsed or Refractory Multiple Myeloma (RRMM) - Master Protocol
Latest Information Update: 17 Jul 2024
At a glance
- Drugs Belantamab mafodotin (Primary) ; Belumosudil (Primary) ; Dexamethasone (Primary) ; Evorpacept (Primary) ; Isatuximab (Primary) ; Pegenzileukin (Primary) ; SAR 439459 (Primary) ; Pomalidomide
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sanofi; Sanofi-Aventis Recherche & Developpement
- 05 Jul 2024 Planned End Date changed from 2 Mar 2028 to 31 Mar 2028.
- 05 Jul 2024 Planned primary completion date changed from 30 Jun 2027 to 28 Jul 2027.
- 24 May 2024 Planned End Date changed from 2 Dec 2027 to 2 Mar 2028.